These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. TA-CIN, a vaccine incorporating a recombinant HPV fusion protein (HPV16 L2E6E7) for the potential treatment of HPV16-associated genital diseases. Hibbitts S Curr Opin Mol Ther; 2010 Oct; 12(5):598-606. PubMed ID: 20886392 [TBL] [Abstract][Full Text] [Related]
3. Vaccinia-expressed human papillomavirus 16 and 18 e6 and e7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia. Baldwin PJ; van der Burg SH; Boswell CM; Offringa R; Hickling JK; Dobson J; Roberts JS; Latimer JA; Moseley RP; Coleman N; Stanley MA; Sterling JC Clin Cancer Res; 2003 Nov; 9(14):5205-13. PubMed ID: 14614000 [TBL] [Abstract][Full Text] [Related]
4. Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins. Davidson EJ; Boswell CM; Sehr P; Pawlita M; Tomlinson AE; McVey RJ; Dobson J; Roberts JS; Hickling J; Kitchener HC; Stern PL Cancer Res; 2003 Sep; 63(18):6032-41. PubMed ID: 14522932 [TBL] [Abstract][Full Text] [Related]
5. Human papillomavirus vaccines. Stanley MA Curr Opin Mol Ther; 2002 Feb; 4(1):15-22. PubMed ID: 11883690 [TBL] [Abstract][Full Text] [Related]
6. An improved rearranged Human Papillomavirus Type 16 E7 DNA vaccine candidate (HPV-16 E7SH) induces an E7 wildtype-specific T cell response. Ohlschläger P; Pes M; Osen W; Dürst M; Schneider A; Gissmann L; Kaufmann AM Vaccine; 2006 Apr; 24(15):2880-93. PubMed ID: 16472545 [TBL] [Abstract][Full Text] [Related]
7. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Welters MJ; Kenter GG; Piersma SJ; Vloon AP; Löwik MJ; Berends-van der Meer DM; Drijfhout JW; Valentijn AR; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; Melief CJ; van der Burg SH Clin Cancer Res; 2008 Jan; 14(1):178-87. PubMed ID: 18172269 [TBL] [Abstract][Full Text] [Related]
8. Human papillomavirus vaccines for the prevention and treatment of cervical cancer. Tomson TT; Roden RB; Wu TC Curr Opin Investig Drugs; 2004 Dec; 5(12):1247-61. PubMed ID: 15648945 [TBL] [Abstract][Full Text] [Related]
9. Induction of human papilloma virus E6/E7-specific cytotoxic T-lymphocyte activity in immune-tolerant, E6/E7-transgenic mice. Riezebos-Brilman A; Regts J; Freyschmidt EJ; Dontje B; Wilschut J; Daemen T Gene Ther; 2005 Sep; 12(18):1410-4. PubMed ID: 15843807 [TBL] [Abstract][Full Text] [Related]
10. HPV vaccines. Stanley M Best Pract Res Clin Obstet Gynaecol; 2006 Apr; 20(2):279-93. PubMed ID: 16356772 [TBL] [Abstract][Full Text] [Related]
12. Eradication of established HPV 16-expressing tumors by a single administration of a vaccine composed of a liposome-encapsulated CTL-T helper fusion peptide in a water-in-oil emulsion. Daftarian P; Mansour M; Benoit AC; Pohajdak B; Hoskin DW; Brown RG; Kast WM Vaccine; 2006 Jun; 24(24):5235-44. PubMed ID: 16675074 [TBL] [Abstract][Full Text] [Related]
13. The pathogenesis of advanced cervical cancer provides the basis for an empirical therapeutic vaccine. Ghim SJ; Sundberg J; Delgado G; Jenson AB Exp Mol Pathol; 2001 Dec; 71(3):181-5. PubMed ID: 11733943 [TBL] [Abstract][Full Text] [Related]
14. Optimal induction of HPV DNA vaccine-induced CD8+ T cell responses and therapeutic antitumor effect by antigen engineering and electroporation. Seo SH; Jin HT; Park SH; Youn JI; Sung YC Vaccine; 2009 Sep; 27(42):5906-12. PubMed ID: 19651174 [TBL] [Abstract][Full Text] [Related]
15. A comparative study on the immunotherapeutic efficacy of recombinant Semliki Forest virus and adenovirus vector systems in a murine model for cervical cancer. Riezebos-Brilman A; Walczak M; Regts J; Rots MG; Kamps G; Dontje B; Haisma HY; Wilschut J; Daemen T Gene Ther; 2007 Dec; 14(24):1695-704. PubMed ID: 17928874 [TBL] [Abstract][Full Text] [Related]
16. HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities. Santin AD; Bellone S; Palmieri M; Ravaggi A; Romani C; Tassi R; Roman JJ; Burnett A; Pecorelli S; Cannon MJ Gynecol Oncol; 2006 Mar; 100(3):469-78. PubMed ID: 16249018 [TBL] [Abstract][Full Text] [Related]
17. Comparison of HPV DNA vaccines employing intracellular targeting strategies. Kim JW; Hung CF; Juang J; He L; Kim TW; Armstrong DK; Pai SI; Chen PJ; Lin CT; Boyd DA; Wu TC Gene Ther; 2004 Jun; 11(12):1011-8. PubMed ID: 14985791 [TBL] [Abstract][Full Text] [Related]
18. Spontaneous regression of grade 3 vulvar intraepithelial neoplasia associated with human papillomavirus-16-specific CD4(+) and CD8(+) T-cell responses. Bourgault Villada I; Moyal Barracco M; Ziol M; Chaboissier A; Barget N; Berville S; Paniel B; Jullian E; Clerici T; Maillère B; Guillet JG Cancer Res; 2004 Dec; 64(23):8761-6. PubMed ID: 15574788 [TBL] [Abstract][Full Text] [Related]
19. Update on human papillomavirus vaccines for cervical cancer. Steller MA Curr Opin Investig Drugs; 2002 Jan; 3(1):37-47. PubMed ID: 12054070 [TBL] [Abstract][Full Text] [Related]
20. Strategies against human papillomavirus infection and cervical cancer. Jung WW; Chun T; Sul D; Hwang KW; Kang HS; Lee DJ; Han IK J Microbiol; 2004 Dec; 42(4):255-66. PubMed ID: 15650698 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]